The following video interviews discuss combinations of immunotherapy drugs and immunotherapy plus targeted therapy for the first-line treatment of metastatic renal cell carcinoma (RCC).

Sumanta K. Pal, MD, of the City of Hope National Medical Center in California, USA discusses immunotherapy as a first-line treatment for kidney cancer and the strategy of VEGF blockade with immunotherapy, which is emerging as a possible treatment modality.

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, New York, USA, discusses the potential of existing targeted therapy coupled with immunotherapy to improve overall survival (OS) in patients with kidney cancer.